BioBlast® - Search
FDA approves new dosage regimen for Erbitux® (cetuximab)
The FDA approved a new dosage regimen for Erbitux® (cetuximab) for patients with K-RAS wild-type, EGFR-expressing metastatic colorectal cancer or squamous cell carcinoma of the head and neck. The new dosage regimen allows for fortnightly dosing.
AVEO reports data from Ph I study of ficlatuzumab and cetuximab
AVEO Oncology releases its Q2 FY2020 earnings report. AVEO reported data from its Ph I study of ficlatuzumab and cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC) demonstrated that the products have an acceptable safety profile and showed promising anti-tumour activity in a refractory HNSCC patient population. AVEO also announced that it is evaluating the process to secure additional clinical manufacturing of ficlatuzumab to potentially enable a Ph III clinical trial in 2022.
FDA approves encorafenib/cetuximab combination
Pfizer announces the FDA has approved Braftovi® (encorafenib) in combination with Erbitux® (cetuximab) for the treatment of BRAF600E-mutant metastatic colorectal cancer after prior therapy.
Pre-clinical study results of APZ 001
Researchers release results of pre-clinical study of cetuximab candidate APZ001.
Amgen discloses cetuximab biosimilar under development
Amgen discloses at JP Morgan Healthcare Conference that it is in process development for a cetuximab biosimilar.
MabTech announces successful Ph III trials of cetuximab
MabTech announces successful Chinese Ph III clinical trials for Sorrento’s “biosimilar/biobetter” cetuximab STI-001, and infliximab STI-002.
Product specific reports based on extracts from our BioBlast® database
BioBlast® Editor and Contributing Author
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to recieve our updates via email.